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Results
Eighteen patients were enrolled. The median (range) tumour size and RENAL nephrometry score were 76.5 (70-98) mm and 11 (7) (8) (9) (10) (11) , respectively. After axitinib neoadjuvant treatment, 16 tumours decreased in diameter, with a median size reduction of 17% (64.0 vs 76.5 mm; P < 0.001). The primary outcome was considered achieved in 12 patients who underwent PN for tumours <7 cm. Sixteen patients underwent PN. Axitinib was tolerated in the present study, as has been previously shown in the metastatic setting. Five patients had grade 3 adverse events. Five patients experienced Clavien III-V post-surgery complications. At 2-year follow-up, six patients had metastatic progression, and two had a recurrence.
Introduction
Most RCCs are diagnosed at a localized stage [1] . Radical nephrectomy (RN) is recommended in cases of large (>7 cm) or highly complex tumours when there is a normal contralateral kidney [2] . Partial nephrectomy (PN) better preserves renal function compared with RN and might decrease the incidence of cardiovascular events and improve survival [3, 4] .
Partial nephrectomy is feasible in some T2 tumours [5] , but it is technically challenging and not considered the standard of care. A recent meta-analysis showed lower recurrence and lower cancer-specific mortality for PN but identical all-cause mortality between PN and RN, respectively [6] ; therefore, there is a rationale to downstage large renal tumours (cT2) to be able to perform PN and preserve the renal parenchyma.
Tyrosine kinase inhibitors (TKIs) are used to treat metastatic RCC and can decrease the size of the primary tumour [7] [8] [9] [10] . For this reason, TKIs have been investigated in the neoadjuvant setting to facilitate surgery in locally advanced tumours [8, 11] . Sunitinib, given during two cycles, has been the most studied drug [12, 13] . Axitinib is an oral, vascular epidermal growth factor receptor 1-3, c-KIT, and plateletderived growth factor receptor inhibitor approved in 2012 to treat metastatic RCC after failure of prior systemic therapy. Axitinib is theoretically more potent than first-generation TKIs with regard to vascular epidermal growth factor receptor inhibition, which was why it was of interest in the present study. Axitinib achieved an objective response rate of 19% in a phase III study vs sorafenib in second-line therapy of patients with metastatic RCC [14] .
The aim of the present study was to evaluate the ability of neoadjuvant axitinib to downstage localized cT2 renal tumours for which PN was initially considered 'not appropriate' according to guidelines.
Patients and Methods
The study was designed as an open-label, non-randomized, multicentre, phase II trial and was registered with clinicaltrials.gov (NCT02597322). All patients had a cT2a N0NxM0 renal tumour according to the 2009 TNM classification. After patient consent had been obtained, a biopsy was systematically performed to ensure the presence of a clear-cell component. Eligible patients had to have normal renal function (Modification of Diet in Renal Disease [MDRD]-estimated GFR [eGFR] ≥60 mL/min) and an Eastern Cooperative Oncology Group performance status of 0 or 1. The decision that the tumour was not suitable for PN was taken according to usual practice, current guidelines and physician experience, and was discussed during multidisciplinary RCC tumour board meeting. The institutional review board ethics committee approved the obtaining of informed consent before patient enrolment.
The main exclusion criteria included evidence of metastatic disease on body CT, pre-existing uncontrolled hypertension or significant cardiovascular disease, current use or anticipated need for treatment with drugs that have known CYP3A4 or CYP1A2 interactions, and the requirement of anticoagulant therapy with oral vitamin K antagonists.
Axitinib 5 mg was given twice daily, with dose titration carried out according to individual tolerability as is standard practice. Patients who tolerated axitinib with no adverse events (AEs) > grade 2 during a 2-week period had their dose progressively increased to 7 mg twice daily and to a maximum of 10 mg twice daily.
Patients were followed using renal CT every 2 months. The total duration of axitinib treatment ranged from 2 to 6 months according to radiological response. If tumour size increased, the patient was treated with RN. If tumour size remained stable or decreased, axitinib was pursued.
The last CT image before surgical treatment guided the surgeon's decision between standard (RN) and experimental treatment (PN). The final decision on the type of surgery was left to the surgeon's discretion, according to tumour response with axitinib and his/her expertise. PN was performed using an open or robot-assisted approach according to the surgeon's working environment. Selected centres included experienced surgeons accustomed to complex PNs.
The primary outcome measure was the number of patients receiving PN for a cT1 tumour <7 cm at a maximum of 6 months after starting axitinib.
Secondary outcome measures included the objective response rate according to Response Evaluation Criteria in Solid Tumours (RECIST), the safety of axitinib, renal function assessed by eGFR according to the MDRD formula and renal scintigraphy, and the rate of surgical complications. Side effects were considered separately as AEs and serious adverse events (SAEs). AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 classification. The intensity of an SAE could be mild, moderate or severe. Surgical complications were graded according to Clavien classification.
All data were collected prospectively via an electronic case report form. Results are given as either number (%) for qualitative variables or, mean or median with SD, interquartile range or range for quantitative variables. Changes in measured variables such as tumour diameter, RENAL nephrometry score and eGFR were analysed using the Wilcoxon signed-rank test, with P < 0.05 considered statistically significant.
Results
A total of 18 patients were enrolled ( Fig. 1) , including seven women and 11 men, with a mean (range) age of 60 (36-83) years. All patients underwent kidney tumour biopsy before inclusion in the study. Patient and tumour characteristics are detailed in Table 1 . The median (range) baseline tumour size was 76.5 (70-98) mm, and the median (range) RENAL nephrometry score was 11 (7-11). The mean serum creatinine level was 0.8 mg/dL and eGFR was 99.8 mL/min/1.73 m 2 . The International Society of Urological Pathology grades were II, III and IV in 14, 3 and 1 patients, respectively. Axitinib was administered preoperatively for 2, 4 and 6 months in 12, three and three patients, respectively. The dose of axitinib remained at 5 mg twice daily in 12 patients, was increased to 7 mg twice daily in two patients, was increased to 10 mg twice daily in three patients, and was decreased to 3 mg twice daily in one patient. The median (interquartile range [IQR]) interval from treatment cessation to surgery was 6 (3-10) days.
The effects of axitinib on tumour size are summarized in Table 2 and Fig. S1 . Tumour diameter decreased in 16 the patients. The maximum size of the tumours was significantly smaller at the end of treatment than at baseline (64 vs 76.5 mm; P < 0.001). The median reduction in tumour diameter was 12 mm, equating to a 17.1% shrinkage. According to RECIST, partial response and stable disease were reported in four and 13 patients, respectively. In one patient, the maximum tumour diameter increased by 4 mm (5%). It was 87 mm on imaging before surgery, after 57 days of axitinib therapy, vs 83 mm at baseline. The median RENAL nephrometry score decreased from 11 to 10 (P = 0.03). eGFR was not affected by axitinib administration. Four representative cases are illustrated in Fig. 2. A total of 17 patients underwent surgery. The primary outcome was considered achieved in 12 patients (67%) who underwent PN for cT1 tumours <7 cm that were initially cT2 and considered not suitable for PN. Sixteen patients underwent PN: nine with a robotic-assisted and seven with an open approach. A discrete infiltration of peritumoural tissues was often encountered but had minimal impact on surgery. The patient who underwent RN had a tumour size >7 cm after treatment. The surgical variables are summarized in Table 3 .
One month after surgery, the median (range) serum creatinine level and MDRD eGFR were 0.9 (0.5-1.7) mg/dL and 87 (44-137) mL/min, respectively. The mean eGFR 1 month after surgery was significantly decreased by 11 mL/ min (86 vs 97 mL/min; P = 0.011).
Adverse events are summarized in Table S2 . The final pathology results are summarized in Table S1 . Seventeen tumours were pathologically analysed; all of them were clear-cell RCC. Seven tumours were pT3a, four were pT2 and six were pT1. Eight tumours were high-grade III or IV, and nine were grade II. Nine tumours had necrosis with a median (IQR) rate of 25 (20-30)%. There were two (11%) positive margins.
Fifteen patients were followed for a minimum of 2 years. Three patients were excluded from the study prematurely: two patients because of the decision of the investigator at 1 and 4 months post-surgery, and one patient who died at 1 month post-surgery. There were no wound or abdominal wall complications. Four patients had tumour progression during the postoperative follow-up period: three developed pulmonary micronodules and one had bone and hepatic metastases. One of the patients who had metastatic progression also had a recurrence elsewhere in the kidney. Cancer-specific survival data are shown in the Kaplan-Meier curve in Fig. 3 . The mean decrease in eGFR from the day of surgery to 24 months post-surgery was 13 mL/min (84 mL/min at 24 months vs 97 mL/min the day of surgery; P = 0.001). 
Discussion
The use of TKIs has increased survival after metastatic RCC [15, 16] ; however, complete response is rare, and partial response is seen in only 31% of the patients [7] . There has been some interest in the use of TKIs before surgery, and several retrospective studies have shown significant response rates (Table S3 ). The decrease in the size of the primary tumour is usually limited, however, and it is not clear how neoadjuvant treatments can facilitate the extirpation of complex renal tumours. This suggests that, in such complex cases, neoadjuvant treatment should not be considered a standard option, but rather case-by-case discussion should be carried out with an experienced urologist with regard to the possibility of performing PN.
In the present phase II trial, we showed that neoadjuvant axitinib achieved a 22% partial response rate according to RECIST, with 89% of the patients experiencing tumour shrinkage. Furthermore, RENAL nephrometry score decreased in 46% of the cases. Most of the patients finally underwent PN, which suggests that axitinib could make it possible to perform PN in cases when it was initially considered not recommended according to guidelines.
The RECIST response rate of 22% (range 1-46%) was in accordance with other TKI studies [17] . Tumour shrinkage was similar to that of other targeted therapies with which the median reduction of tumour diameter ranged from 8% to 28%, compared with 17% in the present study. The rate of achievement of PN (89%) was higher than in other publications [17] [18] [19] [20] [21] [22] .
Even though the study was designed to evaluate the final rate of PN for tumours <7 cm, initially cT2, the final decision was left at the surgeon's discretion depending on tumour downstaging and his/her surgical expertise. Indeed, the decision to perform a PN or not remains in part subjective, depending on the surgeon's experience and environment, and there is no precise criterion to guide the decision. Nonetheless, while axitinib can reduce the complexity of PN, these cases remain highly challenging and require expert surgeons. Five patients had major complications. We observed urine leak in two patients (12%), which is higher than expected based on classic PN series [23] .
Several agents, such as bevacizumab, sorafenib, sunitinib and pazopanib, have been used in the pre-surgical setting in patients with metastatic RCC (Table S3) . Rini et al. [20] conducted a phase II study of neoadjuvant pazopanib in 25 patients with high-complexity kidney tumours. They reported a decrease in RENAL nephrometry score in 71% and a reduction in tumour volume in 92% of patients. A PN was performed in 20 of the 25 patients (80%). Karam et al. [17] presented a phase II study of neoadjuvant axitinib in 24 patients with cT3a non-metastatic clear-cell RCC to investigate the safety and efficacy of downsizing renal tumours. After 12 weeks of axitinib, the median reduction of the primary renal tumour diameter was 28.3%, 45.8% of patients had a partial response according to RECIST, and 21% of the patients underwent PN. That study was limited by the fact that the authors did not provide a RENAL nephrometry score which could help define the better surgical approach for performing PN and the pre-specified 12-week axitinib treatment period may not have been optimal. In the present study with axitinib, 16 patients experienced tumour shrinkage, and 89% of the patients underwent PN.
The better results obtained with neoadjuvant axitinib could be related to several factors. First, all patients had clear-cell histology, documented with biopsy before inclusion in the trial. Clear-cell histology is most likely to respond to TKIs. Second, preoperative therapy was given for a sufficient period of 2-6 months, which could have maximized the benefits of drug exposure. Third, given the dose titration possibility, five patients had an increased dose of axitinib. Fourth, the mechanism of action of axitinib might confer a better response in the primary tumour compared with other available TKIs [9, 10] . Fifth, the response of the primary renal tumour is perhaps different in the localized setting, as compared to the metastatic setting, where most neoadjuvant or pre-surgical studies have been conducted (Table S3) .
Axitinib was well tolerated overall, and toxicities were easily managed. There were no grade 4 or grade 5 AEs, and none of the SAEs resulted in axitinib discontinuation.
Pathological evaluation showed that 41% of these cT2 tumours were finally pT3a, 47% of the tumours were high grade, and 11% had a positive surgical margin. These pathological results can explain the 22% progression rates of metastatic disease at 2 years' follow-up.
The present results need to be confirmed considering the small number of patients included in the study and the lack of a control arm. Other neoadjuvant studies with immunemodulating therapies will report new outcomes with nivolumab (NCT03055013, NCT02595918), pembrolizumab (NCT02212730), pembrolizumab and cryoablation followed by nephrectomy (NCT03189186), and durvalumab with or without tremelimumab (NCT02762006).
In conclusion, neoadjuvant axitinib is feasible, and even with a modest decrease in size, might favour PN over RN in baseline cT2 localized renal tumours. PN remained highly complex, however, requiring sufficient surgeon expertise and patient information on possible increased morbidity. Nevertheless, the present study may support case-by-case discussion with experienced urologists to consider axitinib as an option for neoadjuvant in this setting. Further studies are warranted to evaluate the impact on recurrence and overall survival.
Supporting Information
Additional Supporting Information may be found online in the Supporting Information section at the end of the article. Figure S1 . Relative decrease in tumour diameter (%). Partial response by RECIST in red. Table S1 . Final pathology. Table S2 . Description of adverse events (AEs). Table S3 . Results of preoperative targeted therapy trials for renal cell carcinoma (adapted from Karam et al. [17] ).
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